Literature DB >> 8497908

The participation of tumor necrosis factor in the pathogenesis of lung allograft rejection in the rat.

R Saito1, J Prehn, X J Zuo, A Marchevesky, J Castracane, P Waters, J Matloff, S C Jordan.   

Abstract

Tumor necrosis factor alpha and beta are polypeptide cytokines with a wide range of metabolic, immunologic, and inflammatory activities. TNF is known to participate in immune mediated injury of native lungs, but a role for TNF in mediating lung allograft rejection (AR) has not been established. In experiments reported here, we assessed the role of TNF in mediating lung AR in a rat model of lung transplantation (BN-->Lew) (RT1n-->RT1l). This model shows florid AR with all grafts completely destroyed by day 6 posttransplant. Graft pathology is characterized by massive lymphocytic infiltrates and hemorrhagic necrosis. Initially, 5 lung allograft recipients in each group were sacrificed on days 1 to 6 posttransplant. Allografts were removed, mRNA isolated, and Northern blotting or RT-PCR performed with blots probed with cDNAs or oligos specific for rat TNF-alpha cyclophylin and gamma-actin. Data were compared with syngeneic transplants (Lew-->Lew) and with normal controls. In addition, frozen lung allograft tissue was examined by indirect immunofluorescence, using antibodies specific for TNF. TNF-alpha mRNA levels were detectable on day 2 posttransplant, and peaked on days 6-7 posttransplant. IF studies showed TNF protein expression in mononuclear cells of rejecting allografts on day 3, peaking on day 6. Both TNF-alpha mRNA and protein levels correlated with maximal AR and hemorrhagic necrosis of grafts. Minimal TNF-alpha mRNA or protein was detected in syngeneic grafts or in contralateral native lungs. We then examined the ability of a rabbit polyclonal anti-TNF-alpha (7000 U/day) and anti-TNF-beta (5000 U/day) with 30% crossreactivity with rat TNF to modify the AR response. For each group, 4-5 left lung transplants were performed as described, and animals treated with anti-TNF-alpha, anti-TNF-beta, (anti-TNF-alpha+anti-TNF-beta) or with preimmune rabbit sera. All animals were sacrificed on day 6 posttransplant. Several pathological categories of inflammation were examined and scored (0-4), with a score of 0 = 0% involvement; 1 = 1-25% involvement; 2 = 26-50% involvement; 3 = 51-75% involvement; and 4 = 76-100% involvement. The mean and SD scores were obtained for all animals in the treatment categories mentioned above, and compared with preimmune-treated controls. Briefly, no differences in perivascular, peribronchial, or peribronchiolar cell infiltrates or edema were seen in treatment groups compared with controls.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497908     DOI: 10.1097/00007890-199305000-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

Review 1.  Tumor necrosis factor-driven cell death in donor organ as a barrier to immunological tolerance.

Authors:  Rosalind L Ang; Adrian T Ting
Journal:  Curr Opin Organ Transplant       Date:  2019-02       Impact factor: 2.640

Review 2.  Lung transplantation: opportunities for research and clinical advancement.

Authors:  David S Wilkes; Thomas M Egan; Herbert Y Reynolds
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

3.  Effects of Mycobacterium tuberculosis on the bioelectric properties of the alveolar epithelium.

Authors:  M Zhang; K J Kim; D Iyer; Y Lin; J Belisle; K McEnery; E D Crandall; P F Barnes
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

4.  In vitro culture of B-lymphocytes derived from Epstein-Barr-virus-associated posttransplant lymphoproliferative disease: cytokine production and effect of interferon-alpha.

Authors:  P Randhawa; T Whiteside; A Zeevi; M Nalesnik; C Alvares; S M Gollin; J Demetris; J Locker
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997 Nov-Dec       Impact factor: 2.723

Review 5.  The regulation of pulmonary immunity.

Authors:  M F Lipscomb; D E Bice; C R Lyons; M R Schuyler; D Wilkes
Journal:  Adv Immunol       Date:  1995       Impact factor: 3.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.